Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024

Rhea-AI Summary

Savara Inc. announces data presentation at ATS 2024 on aPAP diagnosis and laboratory blood test development. Trillium Health to present on GM-CSF antibodies test. Abstracts to be published in AJRCCM supplement.

Savara’s Partner, Trillium Health LLC, to Present Data on the Laboratory Blood Test for Diagnosing aPAP

Company to Host Industry Theater on Pulmonary Alveolar Proteinosis (PAP) with Two World-Renowned Experts

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.

“We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP,” said Matt Pauls, Chair and CEO, Savara. “We are also keen to increase awareness and understanding of this rare and chronic lung disease through our Industry Theater with two aPAP experts.”

ATS 2024 Accepted Abstracts:

Savara
701: Healthcare Burden of Pulmonary Alveolar Proteinosis
Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant
Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT

Trillium Health
702: Development of a Novel Laboratory Test for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Individuals At-Risk for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Poster Session A26: Improving Outcomes in Sarcoidosis, Rare Lung Disease and Lung Transplant
Poster Discussion Session: Sunday, May 19, 2024, 9:15-11:15 AM PDT

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024. For more details about the ATS International Conference please visit https://conference.thoracic.org/index.php.

Industry Theater:

Pulmonary Alveolar Proteinosis (PAP): Pathophysiology, Diagnosis, and Management
Sunday, May 19, 2024, 1:15-2:00 PM PDT

Bruce Trapnell, M.D., M.S. and Tisha Wang, M.D. will provide an overview of PAP, including the burden of this rare lung disease, the hallmark signs and symptoms of autoimmune PAP (aPAP), the most common form of PAP, and the path to diagnosing aPAP.

About aPAP

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disease that belongs to a family of distinct rare lung diseases collectively known as pulmonary alveolar proteinosis (PAP). aPAP represents about 90% of all patients with PAP. While aPAP can affect people of any age, race or sex, onset occurs most frequently in people between the ages of 30 and 40. PAP is characterized by the build-up of surfactant in the alveoli, or air sacs, of the lungs. The surfactant consists of proteins and lipids and is an important physiological substance that lines the inside of the alveoli to prevent the lungs from collapsing. The root cause of aPAP is an autoimmune response against GM-CSF, a naturally occurring protein in the body. Pulmonary macrophages need to be stimulated by GM-CSF to function properly, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering the macrophages unable to perform their tasks, including the clearance of surfactant from the alveoli. In aPAP, the feeling of having trouble breathing is the most common symptom. People with aPAP can also experience chronic cough, fatigue, sputum production, reduced ability to exercise and episodes of fever due to underlying pulmonary infections.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow^® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon Savara’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the outcome of our ongoing and planned clinical trials for our product candidate, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara’s operations and to conduct or continue planned clinical development programs, the ability to successfully develop our product candidate, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as molgramostim that are safe and effective for use as human therapeutics, and the timing and ability of Savara to raise additional capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408391675/en/

Savara Inc. IR & PR

Anne Erickson

Chief Business Officer

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

What is the focus of Savara's presentation at ATS 2024?

Savara will present data on the healthcare burden of Pulmonary Alveolar Proteinosis (aPAP) and the development of a novel laboratory-based autoantibody blood test for aPAP diagnosis.

When will the abstracts be presented at ATS 2024?

The abstracts by Savara and Trillium Health will be presented on Sunday, May 19, 2024, during the Poster Session A26 at 9:15-11:15 AM PDT.

Where will the ATS 2024 International Conference take place?

The ATS 2024 International Conference will be held in San Diego, CA.

Where will the abstracts be published?

The abstracts will be published in a supplement of the American Journal of Respiratory and Critical Care Medicine (AJRCCM) on May 1, 2024.

What is the significance of Trillium Health's presentation at ATS 2024?

Trillium Health will present on the development of a novel laboratory test for the detection of GM-CSF antibodies to aid in the diagnosis of individuals at risk for autoimmune Pulmonary Alveolar Proteinosis (aPAP).